FLT3 and acute leukemia: Besides, to evaluate the efficacy of sorafenib on FLT3-negative acute leukemia, we are doing a multi-center, randomized, phase 3 trial of sorafenib maintenance after allo-HSCT in patients with FLT3-negative acute leukemia (NCT04674345).